The Insider Summary
- What it is
- A long-acting analog of the gut hormone GLP-1, engineered for resistance to enzymatic breakdown and for albumin binding, allowing once-weekly injection or daily oral dosing.
- Why researchers are interested
- It produces substantial, sustained weight reduction and glycaemic improvement, and — unusually for a metabolic drug — has demonstrated a reduction in major adverse cardiovascular events in a dedicated outcomes trial.
- Evidence
- Clinical, at the top of the scale. Multiple large randomised controlled trials with published results, including the STEP weight-management programme and the SELECT cardiovascular outcomes trial.
- Regulatory status
- FDA approved across several products and indications, each specific. Carries a boxed warning for risk of thyroid C-cell tumours based on rodent findings.
- Bottom line
- Semaglutide is the benchmark that every investigational peptide in this space is implicitly measured against. When a compound is described as "like semaglutide but better", the relevant question is whether it has anything resembling this evidence base — usually it does not.
Quick reference
- Compound
- Peptide analog
- Research areas
- Metabolic Research
- Evidence level
- CLINICAL
- Research status
- FDA Approved
- FDA approved
- Yes — for type 2 diabetes (as Ozempic and Rybelsus); chronic weight management and long-term weight maintenance (as Wegovy); reduction of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight (as Wegovy); noncirrhotic MASH with moderate to advanced liver fibrosis (as Wegovy injection)
- Human clinical evidence
- Extensive
- Sequence
An acylated analog of human GLP-1 (7–37) with substitutions at positions 8 and 34 and a C18 fatty diacid chain enabling albumin binding.- Last reviewed
- 17 September 2026
What is semaglutide?
Semaglutide is a peptide drug: an engineered analog of a naturally occurring human hormone. It is sold under several brand names, each corresponding to a distinct approved product and indication set, which is a source of persistent confusion.
The distinction matters because FDA approval is granted per product and per indication, never to a molecule in the abstract. A prescription of one branded semaglutide product is not evidence that the drug is approved for what another product is approved for, and the dosing differs between them.
What unifies them is an unusually large evidence base. The STEP programme established the weight-management effect in randomised placebo-controlled trials [2]. The SELECT trial then tested something harder: whether treating obesity with semaglutide reduces cardiovascular events in people without diabetes [3]. It did, and that result is why cardiovascular risk reduction now appears on the label.
What is semaglutide approved for?
As of the February 2026 revision of the Wegovy prescribing information, Wegovy injection is indicated, in combination with a reduced-calorie diet and increased physical activity [1]:
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight;
- to reduce excess body weight and maintain weight reduction long term in adults and paediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition;
- for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stages F2 to F3) in adults.
Semaglutide is separately approved for type 2 diabetes as Ozempic (injection) and Rybelsus (oral tablets).
Each of those indications is backed by its own trial programme. Note what this list does not include: cosmetic weight loss in people without obesity or a weight-related comorbidity, and any of the uses that circulate informally around GLP-1 drugs.
How does Semaglutide work?
Semaglutide is an agonist at the GLP-1 receptor. Activation enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release, slows gastric emptying, and acts on hypothalamic circuits regulating appetite and satiety. Because insulin secretion is glucose-dependent, the mechanism carries a lower intrinsic hypoglycaemia risk than insulin itself when used alone. The structural modifications — substitution at position 8 to resist DPP-4 cleavage, substitution at position 34, and a C18 fatty diacid linker for albumin binding — extend the half-life from minutes to approximately a week.
Research and clinical evidence
The table below grades the published record separately for each research area, because a compound can be well studied in one context and entirely unstudied in another. Grades follow the Peptide Insider evidence taxonomy.
| Research area | Evidence level | What the published record shows |
|---|---|---|
| Chronic weight management | CLINICAL | The STEP programme of randomised placebo-controlled trials demonstrated substantial mean weight reduction sustained over 68 weeks. |
| Cardiovascular risk reduction | CLINICAL | The SELECT trial demonstrated a reduction in major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, without diabetes. |
| Type 2 diabetes | CLINICAL | Extensive randomised trial evidence supporting approval as Ozempic and Rybelsus. |
| Noncirrhotic MASH with F2–F3 fibrosis | CLINICAL | Added to the Wegovy injection label; supported by a dedicated trial programme in this population. |
Human clinical studies
Studies conducted in people. These carry the most weight, and their absence is itself a finding.
Once-weekly semaglutide in adults with overweight or obesity (STEP 1)[2]
2021- Design
- Randomised, double-blind, placebo-controlled, 68 weeks, with lifestyle intervention
- Population
- Adults with overweight or obesity, without diabetes
- Subjects
- Approximately 1,961 randomised
FindingsSemaglutide 2.4 mg weekly produced substantially greater mean body-weight reduction than placebo over 68 weeks, with a large difference in the proportion of participants achieving clinically meaningful weight loss thresholds.
LimitationsWeight change is the endpoint; the trial was not designed to measure long-term clinical outcomes. Gastrointestinal adverse events were common. Weight regain after discontinuation has been documented in extension work.
Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)[3]
2023- Design
- Randomised, double-blind, placebo-controlled cardiovascular outcomes trial
- Population
- Adults with established cardiovascular disease and overweight or obesity, without diabetes
- Subjects
- Over 17,000 randomised
FindingsSemaglutide 2.4 mg weekly reduced the incidence of major adverse cardiovascular events compared with placebo. This is a hard-outcome result, not a surrogate, and it supported the cardiovascular indication on the Wegovy label.
LimitationsConducted in a specific secondary-prevention population — established cardiovascular disease plus overweight or obesity. Results do not extend to primary prevention in healthy-weight populations.
FDA and regulatory status
Semaglutide is FDA approved across multiple products and indications. Approval is product-specific and indication-specific.
The Wegovy prescribing information carries a boxed warning: "WARNING: RISK OF THYROID C-CELL TUMORS. In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans." [1]
Two practical points follow for readers of this site. First, an approved peptide drug still carries serious warnings — approval is a judgment about benefit relative to risk in a defined population, not a declaration of safety. Second, compounded semaglutide and semaglutide sold outside the regulated supply chain are not the approved products, have not been through this review, and have been the subject of FDA safety communications.
Safety and known risks
Risks are separated into what is documented, what is plausible but unestablished, and what has not been studied. The third column is usually the longest one for an unapproved compound, and it is not a reassurance.
Known risks
Documented in regulatory labelling or published trial safety data.
- Boxed warning for risk of thyroid C-cell tumours, based on rodent findings; human relevance unknown.
- Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
- Gastrointestinal adverse effects — nausea, vomiting, diarrhoea, constipation — are common and are the leading cause of discontinuation.
- Pancreatitis, gallbladder disease, acute kidney injury secondary to dehydration, and diabetic retinopathy complications appear in the labelled warnings.
- Hypoglycaemia risk when used with insulin or insulin secretagogues.
Potential risks
Plausible on mechanism or drug-class grounds, but not established for this compound.
- Loss of lean body mass alongside fat mass during rapid weight reduction is an active area of clinical investigation.
- Weight regain following discontinuation has been documented, raising questions about duration of therapy that trials of fixed length cannot fully answer.
Unknown or insufficiently studied
Questions the published record does not currently answer.
- Very long-term effects over decades of continuous use are not yet characterised — the drug class is too young.
- Effects in populations excluded from the pivotal trials.
Frequently asked questions
Is semaglutide a peptide?
What is semaglutide FDA approved for?
Does semaglutide have a boxed warning?
Is compounded semaglutide the same as Wegovy or Ozempic?
Continue reading
Comparison
Semaglutide vs Tirzepatide vs Retatrutide
One, two and three receptors. Two approved drugs and one investigational compound. What the trials measured, what the labels say, and where the differences actually lie.
Regulation
Are Peptides FDA Approved?
Some peptides are FDA approved drugs. Most compounds sold as "peptides" are not. Here is how to tell the difference, and what approval does and does not mean.
Regulation
Investigational vs Approved Peptides
Investigational, approved, discontinued and unstudied are four different states, and compounds in all four are sold side by side. How to tell them apart.
Peptide Science
What Are Peptides?
Peptides are short chains of amino acids. What separates a peptide from a protein, why the body uses them as signals, and why that makes them both useful drugs and difficult ones.
References
Peptide Insider cites primary sources wherever they exist — regulatory documents, trial registrations and peer-reviewed literature — in preference to secondary summaries.
- 1.U.S. Food and Drug Administration. WEGOVY (semaglutide) — Highlights of Prescribing Information. FDA Drugs@FDA, 2026;NDA 215256, label revised 02/2026.Regulatory
- 2.Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 2021;384(11):989–1002.
- 3.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 2023.